OVERVIEW

Expert Exchanges on the Evolving Treatment Landscape of Acute Lymphoblastic Leukemia is organized by Medical Learning Institute Inc (MLI).

Release Date: Oct 14, 2026
Expiration Date: Oct 13, 2027

Description:
This expert-exchange activity is designed for hematologists/oncologists in academic and community settings and their multidisciplinary teams who manage pediatric and adult patients with acute lymphoblastic leukemia (ALL). Through candid faculty dialogue, the program examines recent clinical advances in induction/consolidation regimens, targeted therapies, and immunotherapies, along with the expanding role of MRD-guided decision-making across the disease continuum. Participants will explore how to translate the latest evidence into personalized, risk-adapted treatment plans for patients with Philadelphia chromosome–positive (Ph+) and Ph-negative (Ph?) B-ALL, and how to implement effective monitoring and management strategies for treatment-related adverse events. By addressing persistent gaps in therapy selection and sequencing, this activity aims to improve remission durability, reduce avoidable toxicity, and optimize long-term outcomes in real-world practice. 

Learning Objectives:
After completing this activity, the participant should be better able to:

  • Describe recent clinical advances in induction/consolidation regimens, targeted therapies and immunotherapies for the treatment of pediatric and adult patients with ALL
  • Translate the latest data on induction/consolidation regimens, targeted therapies and immunotherapies into personalized treatment plans for pediatric and adult patients with Ph+ and Ph? B-ALL across the disease course
  • Implement monitoring and management strategies for adverse events associated with induction/consolidation regimens, immunotherapies and targeted therapies in pediatric and adult patients with ALL
Credits

Credits:
In support of improving patient care, Medical Learning Institute Inc is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education:
Medical Learning Institute Inc (MLI) designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

For Physicians requesting MOC credit, the post-test and evaluation are required in their entirety as well as your ABIM ID number, DOB (MM/DD), and a score of 70% or higher is needed to obtain MOC credit.

Notice to Diplomates: MLI will report any claimed MOC/Lifelong Learning points to the appropriate Board within 4 weeks of completing the activity. Please ensure that you have provided your Board ID number and MMDD of birth. 

For Canadian Physicians:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Medical Learning Institute Inc is an accredited CME-CPD provider by the European Board for Accreditation in Hematology (EBAH).This educational activity has been accredited for a maximum number of 1.0 EBAH CME-CPD credits. Each participant should only collect credits for time that she/he actually spent in the educational activity.

PA:
Medical Learning Institute Inc has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until October 13, 2027. PAs should only claim credit commensurate with the extent of their participation.

Pharmacy:
Medical Learning Institute Inc designates this application-based continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.

Nursing Continuing Professional Development:
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour and 0.66 contact hour in the area of pharmacology.

  • 1 AMA PRA Category 1 Credits™
  • 1 MOC
  • 1 Contact Hours
  • 0.1 CEU
  • 1 AAPA
  • TARGET AUDIENCE

    PhysicianNursingPharmacistPhysician AssistantOncologistsHematologists

    SPECIALITIES

    HaematologyOncologyMedical Oncology

    RELATED ONLINE COURSES